Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for disopyramide

  1. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

    Technology appraisal guidance
    Published
    6 September 2023
    View recommendations

    Sections for TA913